p53 is an important transcriptional regulator that is frequently mutated in cancer. Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters. Despite the transcriptional repression of these genes by aberrant DNA methylation, restoration of p53 resulted in the partial reactivation of both genes. This reactivation is a result of wt p53 binding to its consensus DNA-binding sites within the MASPIN and DSC3 promoters, stimulating histone acetylation, and enhancing chromatin accessibility of their promoters. Interestingly, wt p53 alone did not affect the methylation status of either promoter, suggesting that p53 itself can partially overcome the repressive barrier of DNA methylation. Pharmacologic inhibition of DNA methylation with 5-aza-2 0 -deoxycytidine in combination with restoration of wt p53 status resulted in a synergistic reactivation of these genes to near-normal levels. These results suggest that cancer treatments that target both genetic and epigenetic facets of gene regulation may be a useful strategy towards the therapeutic transcriptional reprogramming of cancer cells.
Introduction
p53 is a sequence-specific DNA-binding tumor-suppressor protein that plays an important role in transcriptional regulation (Kern et al., 1991; Levine, 1997; Vogelstein et al., 2000) . Loss of normal p53 function occurs in a significant fraction of many human tumors, primarily through mutation or deletion of the p53 gene (Hollstein et al., 1991 (Hollstein et al., , 1999 Soussi et al., 2000) .
Consistent with its role as a transcriptional regulator, loss of p53 results in significant and complex changes in patterns of gene expression; many of these p53-target genes are known to be important in maintaining normal cellular behavior (el-Deiry et al., 1993; Polyak et al., 1997; Yu et al., 1999; Maxwell and Davis, 2000; Zhao et al., 2000; Kannan et al., 2001) . A detailed analysis of p53-target genes in intact cells should aid in the dissection of the mechanisms by which p53 regulates gene expression, and provide insights into mechanisms that may cooperate with p53 in controlling gene transcription.
We performed two-color fluorescence cDNA microarray experiments, described herein, to profile gene expression patterns in 10 breast cancer cell lines that were either untreated or infected with either adenoviral p53 or empty vector control (He et al., 1998) . This geneprofiling experiment revealed the tumor-suppressor gene, MASPIN, whose protein product functions to restrict cell motility, invasion, and metastasis and whose expression is frequently lost during human breast carcinogenesis to be a p53-target gene in breast cancer cells (Zou et al., 1994; Seftor et al., 1998; Zhang et al., 2000b; Streuli, 2002) . These data are consistent with earlier studies by Zou et al. (2000) , who identified two closely spaced p53 consensus binding sites in the MASPIN promoter region and found wt p53 to be a positive transcription factor in human prostate cancer cell lines. Although MASPIN has been described as a p53-target gene in prostate tissue, we were surprised to see MASPIN reactivation by wt p53 in breast cancer cells, since we and others have shown MASPIN to be silenced in association with aberrant methylation of its CpG-rich promoter and adoption of an inaccessible chromatin architecture (Domann et al., 2000; Maass et al., 2002) .
In order to investigate a potential link between mt p53-mediated and aberrant methylation-mediated gene silencing, we sought to identify other genes in the p53-responsive gene set revealed by microarray analysis that were similar to MASPIN. To identify such genes, we applied the additional criteria that, like MASPIN, related genes should be expressed in normal mammary epithelial cells and downregulated in breast cancer and have a CpG island promoter that contains a p53-binding site. A gene that met these criteria was DSC3 (Klus et al., 2001) . Similar to MASPIN, the DSC3 protein function acts as an inhibitor of metastatic potential, and herein we show that the DSC3 gene promoter is aberrantly methylated in breast cancer cells.
We used MASPIN and DSC3 as models of endogenous p53-target genes to study the mechanism by which p53 reactivates gene expression from genes whose inappropriate silencing is associated with aberrant cytosine methylation of their promoters. In this study, we show that wt p53 binds to the endogenous MASPIN and DSC3 promoters, despite the presence of promoter methylation, and that concomitant with this binding is an increase in histone acetylation, the adoption of a more accessible chromatin structure, and reactivation of MASPIN and DSC3 gene expression. Notably, wt p53 did not affect MASPIN promoter cytosine methylation, and the levels of gene expression induced by wt p53 were below levels seen in immortalized, nontumorigenic MCF10A breast epithelial cells.
Together these results suggested that the repressive effects of DNA methylation blocked full gene reactivation (Antequera et al., 1990; Nan et al., 1998; Bird and Wolffe, 1999; Ng et al., 1999; Jones and Baylin, 2002) . In support of this possibility, we show that pharmacologic inhibition of DNA methylation prior to the addition of wt p53 produces a synergistic reactivation of MASPIN expression in breast cancer cells that approach levels seen in nontumorigenic, wt p53, unmethylated MASPIN-positive breast epithelial cells. These results indicate that mutation of p53 and aberrant cytosine methylation can cooperate in longterm transcriptional repression. Cancer therapies that target each of these mechanisms may lead to the synergistic reactivation of genes important to the tumorigenic phenotype and reprogramming of the tumor cell.
Results
We performed two-color fluorescence cDNA microarray experiments to profile expression patterns of approximately 5376 genes in 10 breast cancer cell lines that were either untreated or infected with either adenoviral p53 or empty vector control (Polyak et al., 1997; He et al., 1998) . MCF10A, an immortalized, nontumorigenic, mammary epithelial cell line, was used as a common reference. Genes with expression that varied across the cell lines and treatments were identified at the Po0.05 level and used in a multidimensional scaling analysis of the cell lines (Khan et al., 1998) . The resulting plot identified a cluster of eight cell lines that responded to wt p53 and three cell lines that clustered closer to the control treatments and were largely wt p53 nonresponsive (Figure 1 ). Using the eight cell lines that responded to p53, a set of genes was identified that were induced specifically by wt p53. The group of genes included a number of previously identified p53-target genes (Supplemental Figure 1 ), including MASPIN, a tumor- Figure 1 Characteristics of the breast cell lines used in the study and the multidimensional scaling analysis of the gene-profiling experiments in these cells. (a) Multidimensional scaling analysis of untreated breast cells, and those treated with either wt p53 adenovirus or the vector control adenovirus. Each cell line is represented by a colored dot for each of the three treatments; the cell lines are clustered in three-dimensional space based on the changes in gene expression associated with each treatment. The eight cell lines treated with wt p53 that clustered separately from the untreated or mock-treated cells are circled, and consist of UACC1179, UACC 893, BT549, MDA-MB-231, MDA-MB-157, MDA-MB-468, MDA-MB-453, and MCF10A. The three cell lines treated with p53 that cluster closer to the control-treated cells rather than the p53-treated cells are MDA-MB-435, HS578T, and UACC 2087. (b) Table  showing the cell lines studied, the fold induction of MASPIN and DSC3 expression by wt p53 relative to vector-only-infected cells, as determined by two-color cDNA microarray analysis, the methylation status of the MASPIN and DSC3 promoters, as determined by bisulfite genomic sequencing, and their p53 mutation status. DNA sequencing of the p53 gene determined the p53 mutation status of the UACC cell lines, and the p53 mutation status of the remaining cell lines was taken from the literature. n.d., not determined. n.a., not assayed mt p53 and hypermethylation cooperate to silence genes MM Oshiro et al suppressor gene frequently lost in breast cancer (Zou et al., 1994 (Zou et al., , 2000 Seftor et al., 1998; Zhang et al., 2000a; Streuli, 2002) . The microarray results for MASPIN were confirmed by RT-PCR and Western blot analysis ( Figure 7 and Supplemental Figure 2 ). It is important to note, however, that wt p53 was only able to partially restore MASPIN expression relative to the basal levels seen in MCF10A (see Figure 7) .
DSC3 was another p53-responsive gene identified by multidimensional scaling that was similar to MASPIN in that it is downregulated in breast cancer (Klus et al., 2001) , and has a CpG island promoter that contains a p53-binding site. Similar to MASPIN, the 5 0 region of the DSC3 gene is aberrantly methylated in breast cancer cells (Supplemental Figure 3) and p53 could only partially restore DSC3 to the basal levels seen in MCF10A (see Figure 7) .
We used these two genes in subsequent experiments to analyse the mechanism by which wt p53 reactivates MASPIN and DSC3 gene expression and attenuates their epigenetic silencing. We sought to determine if wt p53 bound to its consensus sites in the MASPIN and DSC3 promoters in intact cells using chromatin immunoprecipitation analysis coupled to real-time PCR (Figure 2a ). Chromatin from uninfected and wt p53-infected UACC1179 and MDA-MB-231 cells were immunoprecipitated using a wt p53 antibody. Following recovery of the immunoprecipitated DNA, p53 binding to the MASPIN and DSC3 promoters was analysed by real-time PCR using TaqMan chemistry, the primers bracketing the p53-binding site. In both cell lines, infection with wt p53 resulted in increased p53 binding to the MASPIN and DSC3 promoters when compared to uninfected cells (Figure 2b ). Although MDA-MB-231 had a nominal increase in p53 binding at the DSC3 promoter, these results were reproducible in three independent experiments, and likely reflect the inability of p53 alone to increase the expression of the DSC3 gene in MDA-MB-231, and further suggests that the aberrant methylation of the DSC3 promoter may be a significant impediment to gene reactivation (see Figure 1b) . Taken together, the results from the microarray experiments and the chromatin immunoprecipitation experiments indicate that MASPIN and DSC3 promoters are direct target genes of p53.
Aberrant cytosine methylation of the MASPIN and DSC3 promoters is an important facet of gene regulation associated with their inappropriate silencing. As the reactivation of MASPIN and DSC3 occurs within the first 24 h after addition of wt p53, not enough time had elapsed to allow for a passive demethylation of these promoters; however, it is possible that p53 was invoking an active demethylation process. To determine if p53-mediated gene reactivation was associated with an active demethylation of the MASPIN and DSC3 promoters, we performed bisulfite sequence analysis on DNA isolated from untreated UACC1179 and MDA-MB-231 cells and cells infected with wt p53 for 24 h. The MASPIN promoter of untreated UACC1179 and MDA-MB-231 are heavily methylated and, following the forced overexpression of wt p53, neither UACC1179 ) p53 binds the MASPIN promoter in vivo in wt p53-infected breast cancer cells. p53 binding to the MASPIN and DSC3 promoters was measured in UACC 1179 and MDA-MB-231 after no treatment or after 24 h of infection with wt p53 using a chromatin immunoprecipitation assay coupled to realtime PCR analysis. Chromatin was immunoprecipitated from the normal cell types with the p53 antibody (clone DO1). MASPIN and DSC3 promoter-specific real-time PCR was performed on DNA from the immunoprecipitated chromatin, and the threshold bar for C t determination was set within the linear range of the PCR amplification. We calculated fold enrichment of p53 binding by the comparative C t method. A representative real-time PCR graph is shown and the average fold enrichment of p53 binding (7s.e.m.) from three independent experiments is shown below the graphs Another facet of epigenetic regulation, which has previously been linked to aberrant cytosine methylation, is histone acetylation state. MCF10A (MASPIN and DSC3 positive) and the breast cancer cell lines UACC1179 and MDA-MB-231 (MASPIN and DSC3 negative) were analysed in the region of differential cytosine methylation for histone acetylation status by chromatin immunoprecipitation using antibodies specific for acetylated histones H3 and H4. Results from these experiments show that the promoters of MASPIN and DSC3 in breast cancer cells are associated with hypoacetylated histones H3 and H4, and this acetylation state is consistent with the aberrant methylation of the gene promoters and the selective silencing of these two genes ( Figure 4 ). In contrast, the GAPDH promoter was enriched for acetylated histones H3 and H4 in all three cell lines (Supplemental Figure 5) As wt p53 is known to associate with histone acetyltransferases and stimulate histone acetylation at target genes (Gu et al., 1997; Barlev et al., 2001; Espinosa and Emerson, 2001 ), we determined the acetylation state of histones H3 and H4 at the MASPIN and DSC3 promoters in untreated UACC1179 and MDA-MB-231 cells and those infected with either adenoviral p53 or empty vector control ( Figure 5 ). In both UACC1179 and MDA-MB-231, wt p53 produced an increase in H3 and H4 acetylation within the MASPIN promoter region, whereas infection with the empty vector-control adenovirus had no effect on their acetylation state. The histone acetylation state of the GAPDH promoter did not change significantly following wt p53 expression in MDA-MB-231 cells, while histone acetylation of the GAPDH promoter decreased approximately two-fold for both histones H3 and H4 in UACC1179. These results indicate that the observed increase in histone acetylation mediated by wt p53 was selective for the MASPIN and DSC3 promoters (Supplemental Figure 6a and b) .
In addition to changes in histone modification, other localized changes in the chromatin architecture are likely to occur when gene transcription is reactivated. To test this possibility, we analysed the chromatin structure of the MASPIN promoter by measuring the accessibility of MspI to its cognate site in the MASPIN promoter in uninfected, vector-control-infected, and wt p53-infected UACC1179 and MDA-MB-231 cells, using a real-time linker-mediated PCR approach. In UACC1179, p53 induced a 14-fold increase in MASPIN promoter accessibility, and in MDA-MB-231, p53 induced a 21-fold increase in MASPIN promoter accessibility Figure 6 ). Despite the increase in chromatin accessibility following wt p53 infection of the tumor cells, it is important to note that MASPIN promoter accessibility did not return to the basal accessibility seen in MCF10A cells.
Taken together, these data suggest that wt p53 reactivates MASPIN and DSC3, at least in part, by directing an increase in the acetylation of histones associated with the MASPIN promoter and inducing a more accessible chromatin architecture. The incomplete reactivation of MASPIN and DSC3 to normal levels suggested that wt p53 is not sufficient to completely overcome aberrant promoter methylation and its associated repressive effects. If this were the case, then inhibition of DNA methylation should diminish these repressive effects and allow for increased gene reactivation.
In a strategy to reverse the genetic (mt p53) and epigenetic (promoter methylation) aberrations associated with the loss of MASPIN and DSC3 gene expression, we treated UACC1179 and MDA-MB-231 with the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine, following which we infected the cells with wt p53 for 24 h. MASPIN and DSC3 expression were analysed by quantitative real-time PCR using TaqMan probe/primers (Figure 7 ). While 10 mm 5-aza-2 0 -deoxycytidine alone or p53 alone had a small effect on MASPIN and DSC3 expression, when the two treatments were combined they produced a synergistic effect on reactivation of both genes with levels of expression approaching the basal levels seen in MCF10A. These results suggest that mt p53 and aberrant DNA methylation participate in the silencing of gene expression through independent, but interrelated, mechanisms of transcriptional control.
Discussion
The purpose of this study was to investigate a potential link between p53, gene promoter methylation and 0 -deoxycytidine-treated, wt p53-treated, and 5-aza-2 0 -deoxycytidine þ wt p53-treated UACC1179 and MDA-MB-231 cells were reverse-transcribed, amplified by real-time PCR in the presence of a MASPIN-specific TaqMan probe, and results quantitated using the comparative C t method. A representative real-time PCR graph is shown and the average reactivation of MASPIN and DSC3 expression (7s.e.m.) from three independent experiments is shown to the right of the graphs Figure 6 p53 increases accessibility of the MASPIN promoter in breast cancer cells. Intact nuclei were isolated from MDA-MB-231 and UACC 1179 after no treatment or after 24 h of infection with wt p53. These nuclei were digested in vivo with MspI, for which there is a single site in the MASPIN promoter. Production of a PCR product following amplification was monitored and quantitated by realtime PCR. Increased amounts of PCR product reveal the presence of accessible chromatin. These experiments were repeated independently three times with similar results mt p53 and hypermethylation cooperate to silence genes MM Oshiro et al and DSC3, both of which are involved in suppression of the metastatic phenotype (Seftor et al., 1998; Tselepis et al., 1998; Zhang et al., 2000a, b; Klus et al., 2001) . MASPIN has previously been identified as a p53-target gene in prostate cells (Zou et al., 2000) , where the MASPIN promoter is unmethylated, while DSC3 was identified as a p53-target gene as a part of the present study.
The results show that the adenoviral reintroduction of wt p53 stimulated gene reactivation through an increase in histone H3 and H4 acetylation of the MASPIN and DSC3 promoters. This mechanism of p53-mediated gene activation through increases in histone acetylation of the target promoters is in general agreement with other recent reports (Gu et al., 1997; Barlev et al., 2001; Espinosa and Emerson, 2001) . Concomitant with the increase in histone acetylation was a change in chromatin architecture; the promoter became more accessible to DNA-binding proteins, as measured by MspI accessibility to its cognate site in the MASPIN promoter. As it is unlikely that histone acetylation alone is sufficient to change chromatin architecture in this fashion, it is probable that wt p53 or p53-mediated histone acetylation subsequently recruits other factors responsible for making the region accessible to DNAbinding proteins, such as the SWI/SNF complex (Lee et al., 2002) .
Although wt p53 was by itself, sufficient for gene reactivation, wt p53 was not sufficient to bring MASPIN and DSC3 gene expression to levels seen in the immortalized, but nontumorigenic, human mammary epithelial cell line MCF10A. Consistent with this observation are the data which show wt p53 alone cannot stimulate reacetylation of histones or chromatin opening to the levels seen in MCF10A. These results suggest that the aberrant methylation that is present in these promoters maintains a repressive effect on gene expression. Indeed, bisulfite sequence analysis revealed that wt p53 did not induce a general demethylation of its target promoters. These data indicate that the repressive mechanisms associated with aberrant cytosine methylation, namely recruitment of histone deacetylase complexes and adoption of an inaccessible chromatin state (Antequera et al., 1990; Nan et al., 1998; Bird and Wolffe, 1999; Ng et al., 1999; Wade et al., 1999) , can partially resist the positive regulatory effects induced by wt p53, namely increased histone acetylation and an 'opening' of chromatin. As such, we hypothesized that inhibition of the epigenetic mechanism of DNA methylation coupled with the repair of genetic defects through the adenoviral introduction of wt p53 would enhance gene reactivation.
To test this hypothesis, we treated breast cancer cells with the inhibitor of DNA methylation 5-aza-2 0 -deoxycytidine (Taylor and Jones, 1979; Jones and Taylor, 1980) in combination with the reintroduction of wt p53. Results showed that this combination produced a synergistic increase in the expression of both MASPIN and DSC3 in breast cancer cells. In summary, these results indicate that genetic and epigenetic mechanisms of gene control can cooperate in the long-term silencing of gene expression in human cancer cells. By extension, as silencing of MASPIN and DSC3 are linked to the increased metastatic behavior in tumor cells, the data presented suggest that cancer therapies that target both genetic and epigenetic facets of gene regulation may provide a new approach to the transcriptional reprogramming of cancer cells.
An important question that emerges from these studies involves the relationship between p53 and aberrant methylation of p53-target gene promoters. Are mutations in p53 and aberrant methylation of p53-target gene promoters two distinct events with independent probabilities or does mutation of p53 influence the probability of aberrant methylation? One mechanism by which p53 could increase aberrant methylation is if p53 functions, in part, to protect target promoters from methylation through its DNA-binding activity. Once wt p53 DNA-binding activity is lost, the p53-target regions would become permissive to cellular machinery responsible for de novo cytosine methylation. Experiments that address this possibility could identify a new mechanism by which p53 maintains genomic integrity.
Materials and methods

Cell culture, adenoviral infections, and drug treatments
The MCF10A, MDA-MB-435, MDA-MB-231, MDA-MB-157, MDA-MB-468, BT549, and HS578T breast cancer cells were obtained from the American Type Culture Collection (Rockville, MD, USA). The early passage sporadic breast cancer cell lines were developed and maintained at the Arizona Cancer Center Cell Culture Core Facility. The UACC1179 and UACC2087 cells were derived from pleural effusions, while UACC893 was derived from a primary tumor (Meltzer et al., 1991; Thompson et al., 1993; Trent et al., 1993) . MDA-MB-435 and MDA-MB-231 were maintained in RPMI 1640 containing 5% fetal bovine serum supplemented with 50 mg/ ml pen/strep. MDA-MB-468, BT549, and HS578T were maintained in RPMI 1640 containing 10% fetal bovine serum supplemented with 50 mg/ml pen/strep. MDA-MB-453, MDA-MB-157, UACC1179 and UACC2087 were maintained in M15 containing 5% fetal bovine serum supplemented with 50 mg/ml pen/strep. MCF10A was maintained in mammary epithelial growth media (Cell Applications, Inc., San Diego, CA, USA).
Recombinant adenovirus serotype 5 containing wt p53 with a GFP detection marker (p53/GFP) or with GFP alone (GFP) were the kind gifts of Bert Vogelstein and were propagated at the Gene Transfer Vector Core, University of Iowa (He et al., 1998) . Breast cancer cell lines were grown, counted, and then infected with 200 plague forming units (pfu) of either GFP adenovirus 5 or p53/GFP adenovirus 5. After 24 h of infection, total RNA was isolated from infected (p53/GFP), mock infected (GFP), and nontreated (no infection) cells. Infection efficiency was monitored by scoring cells for GFP production using flow cytometry and fluorescence microscopy; each virus resulted in X95% infection efficiency.
For 5-aza-2 0 deoxycytidine treatments, cells were grown at low density in six-well plates and treated with 10 mm 5-aza-2 0 -deoxycytidine (Sigma, St Louis, MO, USA) dissolved in 1 Â PBS on day 0 and day 2. In experiments where cells were treated with 5-aza-2 0 -deoxycytidine and the wt p53 adenovirus, the cells were exposed to the same 5-aza-2 0 -deoxycytidine mt p53 and hypermethylation cooperate to silence genes MM Oshiro et al dosing scheme as described above, but were also exposed to 200 pfu/cell on day 3, 24 h prior to RNA isolation. On day 4, total cellular RNA was isolated from each of the samples.
Nucleic acid isolation
Total RNA was isolated from cells using an RNeasy s Mini or Midi Kit (Qiagen, Valencia, CA, USA), and genomic DNA was isolated using the QIAamp s DNA Mini Kit (Qiagen, Valencia, CA, USA). RNA and DNA samples were quantitated by UV absorbance measurements at 260 nm.
p53 genotyping
The cell lines UACC893, UACC1179, and UACC2087 were grown to near confluence, harvested by trypsinization, and DNA was isolated. Genomic DNA (50 mg) from each of the cell lines was sent to the Molecular Diagnostic Laboratory, Institute for Molecular and Human Genetics, Georgetown University Medical Center for analysis. Exons 2-10 and approximately 20 bp of flanking intron regions of the p53 gene were PCR amplified followed by Big Dyet (Applied Biosystems, Foster City, CA, USA) sequencing to determine the status of the p53 gene in these cell lines.
Microarray fabrication
cDNAs were printed onto amino-alkyl silane glass slides (Telechem International, San Jose, CA, USA) using four quilltype pins (catalog number SMP4, Telechem International) mounted onto an OmniGrid robot (GeneMachines, San Carlos, CA, USA) (Schena et al., 1995) . In addition to the 5184 sequence-verified IMAGE consortium clones (catalog number gf200, Research Genetics, Carlsbad, CA, USA), a set of 88 human housekeeping genes (Research Genetics, Carlsbad, CA, USA) and Cy3/Cy5 end-labelled oligonucleotides were placed strategically into the array to aid in data normalization, measurement of nonspecific hybridization, and identification of the corners of the array. Additionally, a set of 104 IMAGE consortium clones representing known genes of interest, but not found in gf200, were purchased from Research Genetics and included in the microarray. A list of the clones on the arrays can be found at http://azcc-microarray.arl.arizona.edu. In all, 5% of the Research Genetics clones were resequenced following their purchase to further verify the library. The library was found to have an error rate below the 2% Research Genetics specification; in fact no errors were found. Following printing, slides were rehydrated, snap-dried, and UV-cross-linked with 65 mJ of 254 nm light using a Stratalinker. Slides were then washed in 1% SDS for 2 min, rinsed in double-distilled water three times, spun dry, and stored at room temperature (RT) in a desiccator until use.
cDNA microarray analysis
Total RNA (40 mg) was converted to fluorescent first-strand cDNA using the Micromax Direct cDNA Microarray System (NEN Life Sciences, Boston, MA, USA) following the manufacturer's protocols. Labeled cDNA from the two reactions was combined and purified using the Qiaquick PCR Purification Kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocols. After elution from the purification column, probe was lyophilized to dryness, and resuspended in 15 ml hybridization buffer, denatured by boiling for 2.5 min, and added to the cDNA microarray manufactured at the Arizona Cancer Center Microarray Core facility. A coverslip (22 Â 22 mm 2 ) was applied, and the array placed in a hybridization chamber (catalog number HYB-03, GeneMachines, San Carlos, CA, USA) at 621C for 18 h. Following hybridization, arrays were washed by placing them into 50 ml conical tubes containing 2 Â SSC, 0.1% SDS for 5 min, 0.06 Â SSC, 0.1% SDS for 5 min, and 0.06 Â SSC for 2 min, all at RT. Arrays were scanned for Cy3 and Cy5 fluorescence using an Axon GenePix 4000 microarray reader (Axon Instruments, Foster City, CA, USA) and quantitated using GenePix software (Axon Instruments, Foster City, CA, USA).
Multidimensional scaling and microarray data analysis
Multidimensional scaling was performed using BRB-ArrayTools software (http://linus.nci.nih.gov/BRB-ArrayTools. html). Genes were entered into the multidimensional scaling analysis that had a Po0.05 and contained data in at least 24 of 33 hybridizations (1118 genes). Multidimensional scaling analysis using the Euclidean distance metric identified eight p53/GFP-infected cell lines that clustered together; these eight cell lines were further analysed using GeneSpring software (Silicon Genetics, Redwood City, CA, USA) to identify genes whose expression was induced by p53/GFP infection. Global error modeling was used to estimate P-values, and a Bonferroni-corrected P-value of o0.00001 was used to select genes that displayed statistically significant increases in expression across the eight selected cell lines.
RT-PCR analysis
For real-time RT-PCR analysis of MASPIN and DSC3 gene expression, a reverse transcription step was performed using TaqMan s Reverse Transcription Reagents (Roche Molecular Systems, Branchburg, NJ, USA), and 50 ng of total RNA in a 50 ml reaction. The reverse transcription reaction was primed with random hexamers and incubated at 251C for 10 min followed by 481C for 30 min, 951C for 5 min and a chill at 41C. Each PCR reaction consisted of 10 ml of cDNA added to 25 ml of TaqMan s Universal PCR Master Mix (Roche Molecular Systems, Branchburg, NJ, USA), 2.5 ml of gene-specific primer/ probe mix (Assays-by-Design, Applied Biosystems, Foster City, CA, USA), and 12.5 ml of PCR water. The PCR conditions were 951C for 10 min, followed by 40 cycles of 951C for 15 s alternating with 601C for 1 min. MASPIN and DSC3-specific PCR was performed and the data collected using the ABI Prism 7000 real-time sequence detection system (Applied Biosystems, Foster City, CA, USA). The genespecific TaqMan probes were labeled with the 5 0 reporter dye, 6-FAM, and a 3 0 end that contains a nonfluorescent quencher and a minor groove binder. Differences in expression were determined using the equation 2 ÀDCt , where the C t value for each sample is subtracted from the C t value of the control. Primer sequences are available upon request.
Sodium bisulfite genomic sequencing of the MASPIN and DSC3 promoters
Genomic DNA (5 mg) was modified with sodium bisulfite under conditions previously described (Domann et al., 2000) . The MASPIN and DSC3 promoter was amplified from the bisulfite-modified DNA by two rounds of PCR using nested primers specific to the bisulfite-modified sequence of the MASPIN and DSC3 CpG island. Primer sequences are available upon request.
Both rounds of PCR were performed under the same parameters, with 1% of the first round PCR product serving as the template in the second round PCR. PCR amplification was performed under the following conditions: 941C for 4 min followed by five cycles of 941C for 1 min, 561C for 2 min, 721C for 3 min, then 35 cycles of 941C for 30 s, 561C for 2 min, 721C for 1.5 min, and ending with a final extension of 721C for 6 min.
The resultant PCR product was cloned into a TA vector according to the manufacturer's instructions (pGEM-T-Easy cloning kit (Promega)). In all, 10 positive recombinants were isolated using a Qiaprep Spin Plasmid Miniprep kit (Qiagen) according to the manufacturer's instructions and sequenced on an ABI-automated DNA sequencer. The methylation status of individual CpG sites was determined by comparison of the sequence obtained with the known MASPIN sequence. The number of methylated CpGs at a specific site was divided by the number of clones analysed (minimum of 10 in all cases) to yield a per cent methylation for each site.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitations using the acetyl-histone H3 and H4 antibodies were performed according to the manufacturer's instructions (Upstate Biotech, Lake Placid, NY, USA) with slight modifications . Cells were rinsed in 1 Â HBSS with 0.1% EDTA and treated with 1% formaldehyde for 10 min at 371C to form DNA-protein crosslinks. The cells were rinsed in ice-cold 1 Â HBSS with 0.1% EDTA containing protease inhibitors (1 mm PMSF, 1 mg/ml aprotinin, 1 mg/ml pepstatin A), scraped and collected by centrifugation at 41C. Cells were then resuspended in a PIPES buffer (5 mm PIPES pH 8.0, 85 mm KCl, 0.5% NP40) containing protease inhibitors, and incubated for 10 min on ice. Cells were then collected by centrifugation and resuspended in a SDS lysis buffer containing protease inhibitors and incubated on ice for 10 min. The DNA-protein complexes were sonicated to lengths between 200 and 1000 bp, as determined by gel electrophoresis. Samples were centrifuged at 14 000 r.p.m. at 41C to spin out cell debris; then the supernatant was diluted 10-fold with chromatin immunoprecipitated (ChIP) dilution buffer containing protease inhibitors. One-tenth of the sample was set aside for input control, and the remaining sample was precleared with Protein A Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Following preclearing, the samples were split into thirds, with two of the three samples treated with acetyl-histones H3 and H4, while the third sample were left as ÀAb control. All samples were rotated overnight at 41C. The chromatinantibody complexes were collected using Protein A Sepharose and then sequentially washed with the manufacturer's low salt, high salt, and LiCl buffers, then washed twice with Tris-EDTA.
p53 ChlPs was preformed as stated above with the following modifications. At the preclearing step protein, A/G PLUS Agarose (Santa Cruz Biotech, Santa Cruz, CA, USA) was used in place of Protein A Sepharose in order to reduce the ÀAb background. Following the preclearing step, the sample was split into half and one portion was incubated with 30 ml of antip53 antibody conjugated to agarose beads (clone DO1 Oncogene, Boston, MA, USA) or 30 ml of protein A/G PLUS agarose. Following an overnight incubation at 41C, the beads were washed with low salt, high salt, and LiCL wash buffers, and then twice with Tris-EDTA.
The chromatin-antibody complexes were eluted and the DNA-protein crosslinks were reversed with 5 m NaCl at 651C for 4 h for all samples, including the input DNA control. All samples were treated with proteinase K, and the acetyl-histone H3-and H4-enriched fractions of genomic DNA were recovered by phenol/chloroform extractions and ethanol precipitations, which were later quantitated using a BioPhotometer (Eppendorf Scientific, Westbury, NY, USA). PCR amplification was performed using Taqman primer/probes specific for the MASPIN and DSC3 promoters. Primer sequences are available upon request.
Real-time PCR was used to analyse ChIP DNA, using the ABI Prism 7000 sequence detector following PE Applied Biosystem's (Foster City, CA, USA) SYBR s Green PCR Master Mix protocol. Real-time PCR was carried out in triplicate on 5 ng of DNA at 951C for 10 min, followed by 40 cycles of 941C for 1 min, 661C for 30 s, and 721C for 1 min for MASPIN and 40 cycles of 941C for 1 min, 681C for 30 s, and 721C for 1 min for GAPDH. MASPIN and GAPDH primers were used at a final concentration of 500 nm for both forward and reverse primers. These conditions have been previously shown to produce a single PCR product (Futscher et al., 2002) .
For each experiment the threshold bar was set within the linear range of the PCR amplification. For the majority of the experiments, the data were analysed with the threshold set at 0.1. The resulting C t and Rn files were exported to Microsoft Excel for data and graphical analysis. C t is the number of PCR cycles necessary to reach fluorescence intensity (an indirect measure of PCR product) within the linear range of PCR amplification. Quantification was determined by applying the comparative C t method, as described in the ABI 7000 sequence detection user guide and others (Litt et al., 2001) . Briefly, fold enrichment was calculated by subtracting the C t value of the ChIP DNA from the C t value of the input DNA fraction and using this value as the power that 2 is raised to (i.e. 2 CtðInputÞÀCtðChIPÞ ).
Chromatin accessibility assays
Chromatin accessibility assays were performed as previously described (Watts et al., 1997) with minor modifications. Ten million cells were washed twice with ice-cold 1 Â PBS, gently scraped and collected by centrifugation. Nuclei were extracted by resuspension of cells in ice-cold 1 Â RSB (10 mm Tris-HCl pH 8, 3 mm MgCl 2 , 10 mm NaCl, 0.05% NP-40). The nuclei were collected by centrifugation, resuspended in appropriate 1 Â restriction endonuclease buffer, and divided into two aliquots of 200 ml/aliquot. Zero or 75 units of MspI (Gibco BRL, Bethesda, MD, USA) was added to the nuclei and incubated at 371C for 15 min. Genomic DNA was isolated using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) and ligated to linkers specific for the MspI ends. The linker 'marks' accessible sites of chromatin, and acts as the primer sequence for PCR along with the MASPIN promoterspecific primer. To increase specific amplification of our band of interest, a second round of PCR is subsequently performed using a 1 : 1000 dilution of the first-round PCR product and adding a second, nested primer that is (1) specific for the genomic region being analysed and (2) internal to the first region-specific primer. Primer sequences are available upon request. First-round PCR was performed using RTG PCR beads (Pharmacia, Piscataway, NJ, USA) to amplify 100 ng of linkered DNA. The initial step in the first-round PCR reaction is a 15-min incubation at 721C, followed by a denaturation at 951C for 2 min and then 25 cycles of 951C for 30 s, 551C for 1 min, 721C for 2 s, and a final extension at 721C for 5 min. The second round of PCR was performed using the ABI Prism 7000 real-time sequence detection system (Applied Biosystems, Foster City, CA, USA). For this nested PCR step, 25 pmol (1 ml) of internal MASPIN-specific primer was added to 5 ml of diluted first-round product (1 : 1000), 19 ml of PCR water, and 25 ml of 2Â SYBR s Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The PCR conditions for this second round of PCR are as follows: a 10 min denaturation at 951C and 40 cycles of 941C for 1 min, 561C for 40 s and 721C for 30 s. SYBR s Green dye is incorporated into doublestranded DNA, allowing real-time monitoring of PCR amplification reactions. Relative levels of chromatin accessibility were determined using the equation 2
ÀDCt . Real-time PCR products were also separated on a 3% TBE agarose gel to verify the presence of a single PCR product of the appropriate size (241 bp).
Relative levels of chromatin accessibility were assessed by comparing the cycles at which each sample reached the threshold cycle (C t ). For each experiment, the threshold bar was set within the linear range of the PCR amplification. Fold differences in accessibility were then determined using the equation 2
ÀDCt , as described above. Real-time PCR products were also separated on a 3% TBE agarose gel to verify the presence of a single PCR product of the appropriate size (241 bp).
